Evidence map›Paper›PMID 42212672›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Ashutosh D Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis, Divaya Bhutani, Giada Bianchi, Victor H Jimenez-Zepeda, Kenshi Suzuki, Suzanne Lentzsch, Antoine Huart and 9 more

Erratum issuedAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Ashutosh D WechalekarNational Amyloidosis Centre and University College London Hospitals, London, United Kingdom.ORCID 0000-0002-4406-7237
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-8780-9512
Vaishali SanchorawalaAmyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, MA.ORCID 0000-0002-6307-2445
Efstathios KastritisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.ORCID 0000-0001-8191-5832
Divaya BhutaniDepartment of Medicine, Division of Hematology, Columbia University Medical Center, New York, NY.
Giada BianchiAmyloidosis Program, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA.
Victor H Jimenez-ZepedaMyeloma Center, Department of Hematology Oncology, Weill Cornell Medicine, New York, NY.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Suzanne LentzschHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY.ORCID 0000-0003-1708-7344
Antoine HuartDepartment of Nephrology and Organ Transplantation, Referral Centre for Rare Kidney Diseases, University Hospital of Toulouse, Toulouse, France.
Alexander CarpinteiroInstitute of Molecular Biology, University of Duisburg-Essen, Essen, Germany.
Eugene Scott SwensonClinical Development, Alexion, AstraZeneca Rare Disease, New Haven, CT.
Zilehuma KhanGlobal Patient Safety, Alexion, AstraZeneca Rare Disease, Boston, MA.
Julia CatiniGlobal Medical Affairs, Alexion, AstraZeneca Rare Disease, Wilmington, DE.
Hrishikesh KulkarniBiostatistics, Alexion, AstraZeneca Rare Disease, Boston, MA.
Brian MeltzerClinical Development, Alexion, AstraZeneca Rare Disease, New Haven, CT.ORCID 0000-0003-3118-030X
Stephen LakeQuantitative Sciences, Alexion, AstraZeneca Rare Disease, Boston, MA.
Michaela LiedtkeStanford Amyloid Center, Stanford University School of Medicine, Palo Alto, CA.ORCID 0000-0001-8945-5850
CARES Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn immunoglobulin light chain (AL) amyloidosis, amyloid fibrils cause organ dysfunction. Anselamimab, a monoclonal antibody, selectively binds to amyloid fibrils, accelerating their clearance.

methodsNewly diagnosed patients with European modification of Mayo 2004 stage IIIa or IIIb AL amyloidosis were randomly assigned to receive anselamimab or placebo with cyclophosphamide, bortezomib, and dexamethasone (with or without daratumumab). The primary end point was a hierarchical composite of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVHs), analyzed using the Finkelstein-Schoenfeld test and win ratio estimation.

resultsAmong 406 randomly assigned patients, the primary end point win ratio for anselamimab versus placebo was 1.11 (95% CI, 0.83, 1.50;

conclusionTreatment with anselamimab, an antifibril antibody used alongside antiplasma cell dyscrasia therapy, while not meeting the primary end point in the overall population, significantly improved ACM and CVH in patients with kappa AL, potentially offering a new therapeutic option for this isotype.

Indexed as

Antibodies, MonoclonalImmunoglobulin Light-chain AmyloidosisAgedAntibodies, Monoclonal, HumanizedBortezomibCyclophosphamideDexamethasoneDouble-Blind MethodFemaleHumansImmunoglobulin Light ChainsMaleMiddle AgedTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBortezomibCyclophosphamidedaratumumabDexamethasoneImmunoglobulin Light Chains

Identifiers

PMID42212672
PMCPMC13340455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.